Investor Presentaiton
KEY EVENTS SINCE THE LAST EARNINGS CALL
Lilly
REGULATORY
.
•
•
•
Announced the completed regulatory submission of tirzepatide for
chronic weight management to the FDA;
Announced the regulatory submission of donanemab for traditional
approval for early Alzheimer's disease in the US and EU;
Announced mirikizumab received approval in the European Union (EU)
for patients with ulcerative colitis and the resubmission to the FDA;
Announced the submission of JaypircaⓇ to the FDA for accelerated
approval in CLL patients based on the Phase 1/2 BRUIN study;
Completed the submission of pirtobrutinib for relapsed or refractory
mantle cell lymphoma in Japan; and
Announced the FDA approval of Jardiance®1 to lower blood sugar along
with diet and exercise in children 10 years and older with type 2 diabetes.
CLINICAL
Presented data at the 2023 Alzheimer's Association International
Conference which showed that donanemab significantly slowed cognitive
and functional decline in people with early symptomatic Alzheimer's
disease; and
Announced topline data from two tirzepatide Phase 3 trials,
SURMOUNT-3 and SURMOUNT-4, in which tirzepatide demonstrated
significant and superior weight loss compared to placebo in both
studies.
OTHER
•
Announced an agreement to acquire DICE Therapeutics, a
biopharmaceutical company that develops novel oral therapeutic
candidates to treat chronic diseases in immunology;
Announced an agreement to acquire Versanis Bio, a private
clinical-stage biopharmaceutical company focused on the
development of new medicines for the treatment of
cardiometabolic diseases;
Announced an agreement to acquire Sigilon Therapeutics, a
biopharmaceutical company that seeks to develop functional
cures for patients with a broad range of acute and chronic
diseases; and
Allocated an additional $50 million to our now $300 million Social
Impact Venture Capital Portfolio, reflecting Lilly's commitment to
going beyond the medicines it makes to have a positive impact on
patients and society through for-profit investments.
1 Jardiance is part of the Boehringer Ingelheim (BI) and Lilly Alliance, and BI holds the marketing authorization for Jardiance
Not for promotional use
2023 Q2 EARNINGS
5View entire presentation